Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non-Current Assets: 2022-2025

Historic Non-Current Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $140.6 million.

  • Centessa Pharmaceuticals' Non-Current Assets rose 240.08% to $140.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.6 million, marking a year-over-year increase of 240.08%. This contributed to the annual value of $40.4 million for FY2024, which is 10.55% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Non-Current Assets stood at $140.6 million, which was down 26.67% from $191.8 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Non-Current Assets registered a high of $191.8 million during Q2 2025, and its lowest value of $993,000 during Q1 2022.
  • For the 3-year period, Centessa Pharmaceuticals' Non-Current Assets averaged around $75.8 million, with its median value being $43.7 million (2024).
  • Per our database at Business Quant, Centessa Pharmaceuticals' Non-Current Assets surged by 2,637.15% in 2023 and then fell by 10.55% in 2024.
  • Centessa Pharmaceuticals' Non-Current Assets (Quarterly) stood at $6.6 million in 2022, then spiked by 588.32% to $45.2 million in 2023, then decreased by 10.55% to $40.4 million in 2024, then spiked by 240.08% to $140.6 million in 2025.
  • Its last three reported values are $140.6 million in Q3 2025, $191.8 million for Q2 2025, and $180.1 million during Q1 2025.